stockrowargenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
Follow ARGX
Alert me
argenex SE (ARGX) EV/FCF
As of 5 November 2026, argenex SE (ARGX) trades at a EV/FCF of 38.4×. Over the past ten years it has ranged from −17,716× (February 2021) to 90.3× (June 2026); the current reading is higher than 84% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 81.7× | — |
| FY2024 | −30.7× | — |
| FY2023 | −8.1× | — |
| FY2022 | −8.9× | — |
| FY2021 | −13.3× | — |
| FY2020 | −13,199× | — |
| FY2019 | 19.2× | 797.40% |
| FY2018 | 2.1× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 41.0× | 4.32% |
| Jun 2026 | 39.3× | (44.65%) |
| Mar 2026 | 71.1× | (12.96%) |
| Dec 2025 | 81.7× | — |
| 25 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| MRNA Moderna, Inc. compare | −73.7× |
| ROIV Roivant Sciences Ltd. compare | −28.1× |
| RVMD Revolution Medicines, Inc. compare | −25.0× |
| GMAB Genmab A/S Sponsored ADR compare | −5.7× |
| REGN Regeneron Pharmaceuticals, Inc. compare | 23.7× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 27.1× |
| RPRX Royalty Pharma PLC compare | 29.5× |
| INCY Incyte Corporation compare | 29.7× |
| ARGX argenex SE | 38.4× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on ARGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement